CN116068172B - 一种用于抗心磷脂抗体定量检测的磁微粒化学发光试剂及试剂盒 - Google Patents
一种用于抗心磷脂抗体定量检测的磁微粒化学发光试剂及试剂盒 Download PDFInfo
- Publication number
- CN116068172B CN116068172B CN202310200206.8A CN202310200206A CN116068172B CN 116068172 B CN116068172 B CN 116068172B CN 202310200206 A CN202310200206 A CN 202310200206A CN 116068172 B CN116068172 B CN 116068172B
- Authority
- CN
- China
- Prior art keywords
- cardiolipin
- glycoprotein
- beta
- reaction
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003429 anti-cardiolipin effect Effects 0.000 title claims abstract description 39
- 238000001514 detection method Methods 0.000 title claims abstract description 33
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 31
- 239000006249 magnetic particle Substances 0.000 title claims abstract description 25
- 102100030802 Beta-2-glycoprotein 1 Human genes 0.000 claims abstract description 110
- 108010023562 beta 2-Glycoprotein I Proteins 0.000 claims abstract description 110
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims abstract description 80
- 238000006243 chemical reaction Methods 0.000 claims abstract description 64
- 239000011324 bead Substances 0.000 claims abstract description 42
- 239000002502 liposome Substances 0.000 claims abstract description 31
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims abstract description 12
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000004913 activation Effects 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 9
- OYBOVXXFJYJYPC-UHFFFAOYSA-N 3-azidopropan-1-amine Chemical compound NCCCN=[N+]=[N-] OYBOVXXFJYJYPC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 claims abstract description 7
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims abstract description 6
- 238000000576 coating method Methods 0.000 claims abstract description 4
- 239000011248 coating agent Substances 0.000 claims abstract description 3
- 239000012286 potassium permanganate Substances 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 64
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 28
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 17
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 17
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 17
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 17
- 239000002244 precipitate Substances 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- 238000000502 dialysis Methods 0.000 claims description 10
- 238000011534 incubation Methods 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 8
- 229940070710 valerate Drugs 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 238000011033 desalting Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 239000005018 casein Substances 0.000 claims description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 5
- 235000021240 caseins Nutrition 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000013504 Triton X-100 Substances 0.000 claims description 3
- 229920004890 Triton X-100 Polymers 0.000 claims description 3
- 229960003964 deoxycholic acid Drugs 0.000 claims description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 239000000385 dialysis solution Substances 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 9
- 150000002148 esters Chemical class 0.000 abstract description 2
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 229940005605 valeric acid Drugs 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 9
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002038 chemiluminescence detection Methods 0.000 description 5
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000872931 Myoporum sandwicense Species 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000003761 preservation solution Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012898 sample dilution Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241001523209 Antissa Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 241001072961 Pogostemon Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- YEIKGFFXYDKWAJ-UHFFFAOYSA-N ethyl hydrogen sulfate;2-piperazin-1-ylethanol Chemical compound CCOS(O)(=O)=O.OCCN1CCNCC1 YEIKGFFXYDKWAJ-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 125000002966 glycerophosphoglycerophosphoglycerol group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 102000036213 phospholipid binding proteins Human genes 0.000 description 1
- 108091011000 phospholipid binding proteins Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/222—Platelet disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310200206.8A CN116068172B (zh) | 2023-03-06 | 2023-03-06 | 一种用于抗心磷脂抗体定量检测的磁微粒化学发光试剂及试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310200206.8A CN116068172B (zh) | 2023-03-06 | 2023-03-06 | 一种用于抗心磷脂抗体定量检测的磁微粒化学发光试剂及试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116068172A CN116068172A (zh) | 2023-05-05 |
CN116068172B true CN116068172B (zh) | 2023-06-20 |
Family
ID=86180324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310200206.8A Active CN116068172B (zh) | 2023-03-06 | 2023-03-06 | 一种用于抗心磷脂抗体定量检测的磁微粒化学发光试剂及试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116068172B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117288948B (zh) * | 2023-06-19 | 2024-06-04 | 无锡嘉润诊断技术有限公司 | 抗凝血酶原抗体检测试剂盒 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0474849B1 (en) * | 1990-04-06 | 1995-09-13 | Yamasa Shoyu Co., Ltd. | Methods for determining antiphospholipid antibodies |
AU644163B2 (en) * | 1990-04-06 | 1993-12-02 | Yamasa Shoyu Co. Ltd. | Methods for determining phospholipids and antibodies thereof |
US5780319A (en) * | 1996-04-19 | 1998-07-14 | Pasteur Sanofi Diagnostics | Immunoassays to detect antiphospholipid antibodies |
CN106405098A (zh) * | 2016-06-30 | 2017-02-15 | 深圳市亚辉龙生物科技股份有限公司 | 抗β2糖蛋白I抗体化学发光免疫检测试剂盒及其制备方法 |
WO2018215506A1 (en) * | 2017-05-23 | 2018-11-29 | Université De Genève | Beta-2-glycoprotein 1 derived peptide and use thereof for treating antiphospholipid syndrome |
CN111323577B (zh) * | 2020-03-10 | 2022-05-03 | 郑州安图生物工程股份有限公司 | 一种抗心磷脂抗体IgG磁微粒化学发光免疫检测试剂盒 |
CN111579772B (zh) * | 2020-05-28 | 2022-04-08 | 珠海丽珠试剂股份有限公司 | 基于免疫磁珠法的检测试剂及其制备方法、试剂盒以及检测方法 |
CN111793122B (zh) * | 2020-07-16 | 2022-02-08 | 珠海丽珠试剂股份有限公司 | 打开天然β2糖蛋白I第V结构域的方法及使用该方法制备的抗原、应用和试剂盒 |
-
2023
- 2023-03-06 CN CN202310200206.8A patent/CN116068172B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN116068172A (zh) | 2023-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU634716B2 (en) | Method for detection of an analyte using acridinium esters and liposomes | |
US5830675A (en) | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis | |
US4868109A (en) | Immunological antibody complex, its preparation and its use | |
CN116068172B (zh) | 一种用于抗心磷脂抗体定量检测的磁微粒化学发光试剂及试剂盒 | |
US20100311185A1 (en) | Detection methods | |
EP0615129A2 (en) | Methods for selectively detecting perinuclear anti-neutrophilcytoplasmic antibody of ulcerative colitis or primary sclerosing cholangitis | |
WO2001032908A1 (fr) | Anticorps monoclonal, hybridome, immunoessai et necessaire a diagnostic | |
CN115932250B (zh) | 一种用于抗aPS/PT抗体定量检测的磁微粒化学发光试剂及化学发光检测试剂盒 | |
US9952230B2 (en) | Method of inhibiting nonspecific reaction in PIVKA-II assay reagent | |
EP0311383A2 (en) | Monoclonal antibody to methamphetamine, preparation of the same, assay method and assay kit of methamphetamine | |
WO1994024568A1 (en) | Stable aqueous fk506 standards | |
US5302512A (en) | Agglutinant complex as blood typing reagent | |
EP3885362A1 (en) | Antibody conjugate | |
US4808522A (en) | Enzyme immunoassays using inorganic pyrophosphatase | |
JPS6314911B2 (zh) | ||
US5990274A (en) | Cyclosporine derivatives and uses thereof | |
EP0928201B1 (en) | Novel glycolipid complexes and their uses | |
US4582699A (en) | Assay of immunoglobulin A protease and the rapid diagnosis of gonorrhea | |
CA1087983A (en) | Rubella virus immunoassay materials and methods for making and using same | |
CN111579799A (zh) | 一种检测尿液中阿尔茨海默病相关神经丝蛋白的荧光免疫层析试纸的制备方法 | |
EP0713094A1 (de) | Heterogener Immunoassay mittels präzipitierbarer Festphase | |
JPS60249058A (ja) | Atlウイルス抗体の測定方法および試薬 | |
JP3033774B2 (ja) | 成人t細胞白血病ウィルス抗体検出用間接凝集反応試薬 | |
JP3846973B2 (ja) | 慢性炎症の判定方法及びキット | |
JPS63290963A (ja) | 酵素標識抗体感作ラテックス及びそれを用いた酵素免疫測定法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Room 205, Building B, No. 36 Huada Road, Houcheng Street, Zhangjiagang City, Suzhou City, Jiangsu Province, China (Zhangjiagang Free Trade Zone Science and Technology Entrepreneurship Park) Patentee after: Suzhou Diyalaibo Biotechnology Co.,Ltd. Country or region after: Zhong Guo Address before: Room 205, Building B, No. 36, Huada Road, Houcheng Street, Zhangjiagang City, Suzhou City, Jiangsu Province, 215634 Patentee before: Suzhou Huizhong Biotechnology Co.,Ltd. Country or region before: Zhong Guo |
|
CP03 | Change of name, title or address |